Related Experiment Video

Updated: Feb 26, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer

Jonathan M Cooper1, Yi-Hung Ou1, Elizabeth A McMillan1

  • 1Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas.

Cancer Research
|July 19, 2017
PubMed

Insights

TANK-binding kinase 1 (TBK1) dysregulation is linked to cancer. This study reveals TBK1 supports cancer cell survival by activating the AKT/mTORC1 pathway, particularly in mesenchymal, Ras-mutant lung cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Dysregulation of TANK-binding kinase 1 (TBK1) is implicated in various diseases, including cancer.
  • While TBK1's role in host defense is known, its broader functions in cell biology and disease remain unclear.
  • Understanding TBK1's context-specific roles is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of TBK1 in cancer cell survival.
  • To elucidate the molecular mechanisms by which TBK1 influences cancer cell biology.
  • To identify specific cancer types dependent on TBK1 for survival.

Main Methods:

  • Utilized broad-scale chemogenomic screening.
  • Employed interactome discovery strategies.
  • Generated data-driven mechanism-of-action hypotheses.

Main Results:

  • TBK1 directly modulates components of the AKT/mTORC1 pathway, both upstream and downstream of mTOR.
  • TBK1 supports the activation and function of the AKT/mTORC1 pathway.
  • Mesenchymal, Ras-mutant lung cancers exhibit a strong dependence on TBK1 for AKT/mTORC1 pathway activation and survival.

Conclusions:

  • TBK1 plays a critical role in supporting cancer cell survival through the AKT/mTORC1 pathway.
  • TBK1 is a potential therapeutic target, especially in specific lung cancer subtypes.
  • Further research into TBK1's multifaceted roles in cancer is warranted.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

853
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K